Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

ImmunityBio (IBRX) Other Gross PP&E Adjustments (2016 - 2025)

ImmunityBio (IBRX) has disclosed Other Gross PP&E Adjustments for 12 consecutive years, with $177.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments fell 3.04% to $177.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $177.0 million, a 3.04% decrease, with the full-year FY2025 number at $177.0 million, down 3.04% from a year prior.
  • Other Gross PP&E Adjustments was $177.0 million for Q4 2025 at ImmunityBio, down from $205.1 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $237.6 million in Q2 2025 to a low of $76.5 million in Q4 2021.
  • A 5-year average of $167.4 million and a median of $182.2 million in 2023 define the central range for Other Gross PP&E Adjustments.
  • Peak YoY movement for Other Gross PP&E Adjustments: soared 128.5% in 2022, then dropped 12.69% in 2025.
  • ImmunityBio's Other Gross PP&E Adjustments stood at $76.5 million in 2021, then soared by 91.06% to $146.2 million in 2022, then rose by 17.21% to $171.4 million in 2023, then rose by 6.51% to $182.5 million in 2024, then fell by 3.04% to $177.0 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Other Gross PP&E Adjustments are $177.0 million (Q4 2025), $205.1 million (Q3 2025), and $237.6 million (Q2 2025).